Evaluation of arginine-glycine-aspartate-containing peptides as inhibitors of equine platelet function

American Journal of Veterinary Research

Volumn 58, Issue 5, 1997, Pages 457-460

  Weiss, Douglas J ^a   Evanson, Oral A ^a   Wells, Roger E ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; GLYCINE; PEPTIDE; RPR 110885; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CELL ADHESION; CELL FUNCTION; HORSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ANIMALS; ARGININE; ASPARTIC ACID; ASPIRIN; BLOOD COAGULATION; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; GLYCINE; HORSES; OLIGOPEPTIDES; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0030968165     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Greatorex JC. Diagnosis and treatment of verminous aneurism formation in the horse. Vet Rec 1977;101:184-186.
2. Maxie MG, Physick-Sheard PW. Aortic-iliac thrombosis in horses. Vet Pathol 1985;22:138-249.
3. Traub-Dargatz JL, Dargatz DA. A retrospective study of vein thrombosis in horses treated with intravenous fluids in a veterinary leaching hospital. J Vet Intern Med 1994;8:264-266.
4. Duncan SG, Movers KM, Reed SM. Alterations in coagulation and hemograms of horses given endotoxins for 24 hours via hepatic portal vein infusions. Am J Vet Res 1985;46:1287-1293.
5. Morris DD. Endotoxemia in horses. A review of cellular and humoral mediators involved in its pathogenesis. J Vet Intern Med 1991;5:167-181.
6. Jarvis GE, Evans RJ. Endotoxin-induced platelet aggregation in heparinized equine whole blood in vitro. Res Vet Sci 1994;57:317-324.
7. Weiss DJ, Geor RJ, Johnston G, et al. Microvascular thrombosis associated with the onset of acute laminitis in ponies. Am J Vet Res 1994;55:606-612.
8. Weiss DJ, Trent AM, Johnston GJ. Prothrombotic events in the prodromal stages of acute laminitis in horses. Am J Vet Res 1995;56:986-991.
9. Rijkenhuizen AB, Nemeth F, Dik KJ. The arterial supply of the navicular bone in adult horses with navicular disease. Equine Vet J 1989;21:418-424.
10. Shinozaki K, Kawasaki T, Kamnayasji J. Species differences in platelet aggregation induced by platelet-activating factor (PAF). Methods Fund Exp Clin Pharmacol 1992;14:663-665.
11. Burrows GE. Hematologic alterations associated with acute E coli endotoxemia, in Proceedings. 1st Int Symp Equine Hematology 1975;505-515.
12. Cambridge H, Lees P, Hooke RE, et al. Anti-thrombotic actions of aspirin in the horse. Equine Vet J 1991;23;123-127.
13. Heath MF, Evans RJ, Poole AW, et al. The effects of aspirin and paracetamol on the aggregation of equine blood platelets. J Vet Pharmacol Ther 1994;17:374-378.
14. Meyers KM, Lindner C, Katz J, et al. Phenylbutazone inhibition of equine platelet aggregation response. Am J Vet Res 1979;40:265-270.
15. Dillon AMR, Heath MF. The effects of tyrphostins B42 and B46 on equine platelet function and protein phosphorylation. Biochem Biophys Res Commun 1995;212:595-601.
16. Foster AP, Andrews MJ, Cunningham FM. Effects of WEB 2086, antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse. Equine Vet J 1992;24:203-207.
17. Wilson DV, Eberhart SN, Robinson, NE, et al. Cardiovascular responses 10 exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086. Am J Vet Res 1993;54:274-281.
18. Samanem J, Ali F, Romoff T, et al. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem 1991;34:3114-3125.
19. Kotze HF, Badenhorst PN, Lamprecht S, et al. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. Thromb Haemost 1995;74:751-757.
20. Cook NS, Kottirsch G, Zerwes HG. Platelet glycoprotein IIbIIIa antagonists. Drugs Future 1994;19:135-159.
21. Doery JCG, Hirsh H, Mustard JF. Energy metabolism in washed human platelets responsive to ADP: comparison with platelets in plasma. Br J Haematol 1973;25:657-673.
22. Kopp KJ, Moore JN, Byars TD, et al. Template bleeding time and thromboxane generation in the horse: effects of three non-steroidal anti-inflammatory drugs. Equine Vet J 1985;17:322-324.
23. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 1973;5:167-179.
24. Weiss DJ, McClay CB, Smith C, et al. Platelet function in the racing Thoroughbred: implications for exercise-induced pulmonary hemorrhage. Vet Clin Pathol 1990;19:35-39.
25. Thakur ML, Walsh L, Malech HL, et al. Indium-111-labeled human platelets: improved method, efficacy, and evaluation. J Nucl Med 1981;22:381-385.
26. Panzer-Knodle S, Taite BB, Mehrotra M, et al. Species variation in the effects of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation. J Pharmacol Toxicol Methods 1993;30:47-53.